8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Apr 13, 2026·SEC
Material company update
Mar 31, 2026·SEC
Xtant Medical Holdings, Inc.(XTNT)Earnings, Financials & Key Ratios
XTNT•AMEX
$0.42
14.0× P/E·Price updated Jul 7, 2026
AboutXtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; OsteoFactor, which contains various proteins and peptides that support bone formation and remodeling; OsteoWrap; and OsteoVive Plus, a growth factor enriched cellular bone matrix. The company also provides 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers Certex spinal fixation, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, Xpress minimally invasive pedicle screw, and Fortex Pedicle screw systems. Additionally, it provides Calix for cervical and thoracolumbar applications, Axle-X interspinous fusion system, Irix-C cervical integrated fusion system, and Irix-A Lumbar integrated fusion system. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.Show more
- Revenue$134M+14.2%
- EBITDA$13M+259.3%
- Net Income$5M+130.2%
- EPS (Diluted)0.03+125.0%
- Gross Margin62.92%+8.2%
- EBITDA Margin9.34%+239.5%
- Operating Margin5.44%+152.8%
- Net Margin3.71%+126.5%
- ROE10.59%+130.4%
XTNT Price & Volume
Xtant Medical Holdings, Inc. (XTNT) stock price & volume — 10-year historical chart
Loading chart...
Operational Volatility Challenges Long Term Value Creation
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Strained
Financial:Healthy
Cash Flow:Mixed
Primary Risk:High operating leverage sensitivity
Key Thesis Takeaways
- Xtant Medical faces significant headwinds as evidenced by the 36.5% revenue contraction in 2026Q1, which underscores the instability of its current transactional business model.
- While the company has successfully reduced total debt to $15.4M from a 2025Q2 peak of $37.1M, the persistent negative retained earnings of -$257.6M highlight a long-term struggle to achieve sustainable profitability.
- Investors should monitor whether the company can stabilize its gross margins, which compressed to 57.3% in 2026Q1, before committing capital to this high-leverage medical device play.
Verdict Logic
the company's inability to maintain consistent operating income, evidenced by the -$2.9M loss in 2026Q1, suggests that the current business model lacks the necessary scale to overcome its high fixed SG&A expenses.
XTNT Growth Metrics
Xtant Medical Holdings, Inc. (XTNT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years8.48%
5 Years20.22%
3 Years32.2%
TTM-0.32%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM115.23%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM114.13%
Return on Capital
10 Years-21.34%
5 Years-10.53%
3 Years-8.14%
Last Year11.21%
XTNT Recent Earnings
Xtant Medical Holdings, Inc. (XTNT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.02-33.3%
$0.01
Rev
$21M+3.6%
$20M
Q2 2026
Mar 31, 2026Metric
Actual
Est
EPS
$0.00+108.2%
$0.00
Rev
$32M+5.2%
$31M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.01+290.5%
$0.01
Rev
$33M+8.1%
$31M
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.02+300.0%
$0.01
Rev
$35M+13.5%
$31M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.02vs $0.01-33.3% | $21Mvs $20M+3.6% |
| Q2 2026 | Mar 31, 2026 | $0.00vs $0.00+108.2% | $32Mvs $31M+5.2% |
| Q4 2025 | Nov 10, 2025 | $0.01vs $0.01+290.5% | $33Mvs $31M+8.1% |
| Q3 2025 | Aug 12, 2025 | $0.02vs $0.01+300.0% | $35Mvs $31M+13.5% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Xtant Medical Holdings, Inc. (XTNT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.42 | $58.84M | 13.98 | 14.21% | 3.71% | 10.59% | — | |
| $9.38 | $1.42B | -9.77 | 24.95% | -21.07% | -443.09% | — | |
| $17.72 | $2.02B | -14.52 | 8.28% | -25.66% | -50.82% | — | |
| $14.82 | $555.26M | 7.80 | 0% | 28.47% | 27.31% | — | |
| $78.83 | $10.63B | 20.11 | 16.65% | 18.92% | 13.04% | — | |
| $218.72 | $3.61B | 25.11 | 11.33% | 8.42% | 16.74% | — |
Compare XTNT vs Peers
Xtant Medical Holdings, Inc. (XTNT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
XTNT SEC Filings & Documents
Xtant Medical Holdings, Inc. (XTNT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when XTNT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
XTNT Frequently Asked Questions
Xtant Medical Holdings, Inc. (XTNT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Xtant Medical Holdings, Inc.'s revenue?
Xtant Medical Holdings, Inc. (XTNT) reported $121.9M in revenue for fiscal year 2025. This represents a 26446% increase from $0.5M in 2008.
How fast is Xtant Medical Holdings, Inc. growing?
Xtant Medical Holdings, Inc. (XTNT) grew revenue by 14.2% over the past year. This is steady growth.
Is XTNT profitable?
Yes, Xtant Medical Holdings, Inc. (XTNT) is profitable, generating $1.8M in net income for fiscal year 2025 (3.7% net margin).
Dividend & Returns
What is XTNT's return on equity?
Xtant Medical Holdings, Inc. (XTNT) has a return on equity (ROE) of 10.6%. This is reasonable for most industries.
What is Xtant Medical Holdings, Inc.'s free cash flow?
Xtant Medical Holdings, Inc. (XTNT) generated $7.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.